Novo Nordisk, the Danish drugmaker behind the blockbuster weight-loss drug Wegovy, is getting a fresh vote of confidence from analysts even as the company navigates a tougher pricing environment in the US. AlphaValue/Baader raised its price target on the stock to 466 Danish kroner, pointing to the potential of the oral version of Wegovy to sustain growth.
The new target implies meaningful upside from recent levels, though the analysts also made a notable adjustment: they cut their 2026 earnings-per-share forecast. That cut isn't a sign of weakening demand. Instead, it reflects a one-off gain from a US pricing program that the analysts decided to strip out of their estimates, cleaning up the numbers to better reflect the underlying business.
Why oral Wegovy matters
Wegovy, a GLP-1 injection, has been a major growth driver for Novo Nordisk, helping the company become one of Europe's most valuable firms. But the injectable market is getting crowded. Rivals like Eli Lilly have launched competing products, and compounding pharmacies have been offering cheaper, often unapproved versions of the drugs, putting pressure on pricing and market share.
The oral form of Wegovy, which is already approved in some markets, is seen as a potential game-changer. An oral pill could appeal to patients who are uncomfortable with injections and could help Novo Nordisk differentiate itself in a rapidly expanding obesity-treatment market. Analysts argue that this oral option gives the company a stronger long-term growth story, even as near-term headwinds persist.
That optimism comes against a backdrop of broader market jitters. Rising US yields and oil prices have kept inflation concerns alive, and European stocks have been volatile. Novo Nordisk's shares have not been immune, but the analyst action suggests that the fundamental story remains intact for those willing to look past the noise.
Pricing pressure and competition
The analysts acknowledge that Novo Nordisk's diabetes and obesity business has faced heavy pricing pressure in the US, its largest market. Insurance companies and pharmacy benefit managers have been pushing for lower prices, and the entry of compounding pharmacies has added another layer of competition. These pharmacies produce versions of the active ingredient in Wegovy and Ozempic, often at a fraction of the cost, which has forced branded drugmakers to respond.
Still, the analysts believe that the oral Wegovy could help offset some of these pressures. If the pill gains traction, it could open up new patient segments and reduce reliance on the injectable supply chain, which has faced periodic shortages. The move to a higher price target suggests that the market may be underestimating the potential of this product line.
For context, Novo Nordisk is not the only European pharma stock under the microscope. European ADRs slipped recently, with Novo Nordisk and Sanofi among the drags, while tech names like SAP gained. That divergence highlights how sector-specific factors, rather than broad market moves, are driving stock performance right now.
What it means for investors
For everyday investors, the key takeaway is that analysts see more upside in Novo Nordisk's stock, but they are also being more conservative about near-term earnings. The price target raise is a signal that the long-term growth story, particularly around oral Wegovy, remains compelling. The EPS cut, meanwhile, is a reminder that one-off items can distort the picture, and it's important to look at the underlying business rather than just the headline numbers.
It's also worth noting that analyst price targets are not guarantees. They represent one firm's view, and the stock could move in either direction. But when a respected firm raises its target while also trimming estimates, it often indicates that the analyst sees a better risk-reward balance over a longer horizon.
Investors should also keep an eye on the competitive landscape. Eli Lilly's Zepbound and other GLP-1 drugs are gaining ground, and the compounding pharmacy issue isn't going away. How Novo Nordisk navigates these challenges, and how quickly oral Wegovy ramps up, will be critical to whether the stock can reach that 466-kroner target.
In the meantime, the broader market environment remains uncertain. Oil prices have climbed on geopolitical tensions, which could feed into inflation and affect central bank policy. For a stock like Novo Nordisk, which is seen as a defensive growth play, such macro factors can influence sentiment even if they don't directly affect the company's fundamentals.
Ultimately, the analyst action is a positive signal, but it's not a reason to rush in. As always, investors should consider their own financial situation and risk tolerance before making any decisions.
